Biocon Ltd. — Capital/Financing Update 2024

Dec 10, 2024

==> picture [132 x 53] intentionally omitted <==

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423

CIN : L24234KA1978PLC003417 www.biocon.com

BIO/SECL/SP/2024-25/136

December 10, 2024

To, To, The Manager The Manager BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate Communication Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai – 400 001 Mumbai – 400 050 Scrip Code – 532523 Scrip Symbol – BIOCON

Dear Sir/ Madam,

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we wish to inform you that the Company has sold 80,00,000 (Eighty Lacs) equity shares of Syngene International Limited (Syngene) in open market through block deal mechanism on December 10, 2024. Post this transaction, the shareholding of the Company in Syngene shall stand at 52.46%.

The details required pursuant to Para A of Part A of Schedule III of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed as Annexure I .

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

MAYANK Digitally signed by MAYANK VERMA VERMA Date: 2024.12.10 16:50:51 +05'30'

---

Mayank Verma Company Secretary & Compliance Officer Membership No: ACS 18776

Encl.: Annexure I

==> picture [132 x 53] intentionally omitted <==

Details required pursuant to Para A of Part A of Schedule III of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Annexure I

Sl. No.	Particulars				Information	Information	Information
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year
				Particulars	Biocon Limited (Consolidated)	Syngene (Consolidated)
					Amount (In mn)	Amount (In mn)	% of BL
				~~Turnover or~~ ~~revenue or~~ Income*	1,56,212	35,792	22.91%
				Net worth*	2,52,748	42,577	16.85%
			*As per the last audited financial statements for year ended March 31, 2024.
2.	Date on which the agreement for sale has been entered into		Not applicable Sale of 80,00,000 (Eighty Lacs) equity shares market through block deal mechanism				in the open
3.	The expected date of completion of sale/ disposal		December 10, 2024
4.	Consideration received from such sale/ disposal		Rs. ~686 Crores The above is gross traded value on the exchange. This is subject to statutory levies, brokerage etc.
5.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/ group companies. If yes, details thereof		Sale of 80,00,000 (Eighty Lacs) equity shares of Syngene International Limited in the open market through block deal mechanism on the platform of the BSE Limited. None of the buyers belong to the Promoter/ Promoter group/ groupcompanies.
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length		No
7.	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations		Not applicable
8.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/ merger, shall be disclosed by the listed entity with respect to such slumpsale		Not applicable